Our data demonstrate FRβ as a potential therapeutic target for both direct cancer therapy causing cytotoxicity to AML cells in both in vivo and in vitro models, as well as indirect therapy targeting the tumor microenvironment of solid tumors such as ovarian cancer through in vitro cytotoxicity of TAMs. The gene discussed is FOLR2; the disease is cancer.